Small Molecule Rescue of ATXN3 Toxicity in C. elegans via TFEB/HLH-30

Autor: J. Alex Parker, Claudia Maios, Yasmin Fardghassemi
Rok vydání: 2021
Předmět:
0301 basic medicine
congenital
hereditary
and neonatal diseases and abnormalities
Longevity
Drug Evaluation
Preclinical
Biology
Chenodeoxycholic Acid
Sulfaphenazole
Neuroprotection
Animals
Genetically Modified
03 medical and health sciences
0302 clinical medicine
Basic Helix-Loop-Helix Transcription Factors
medicine
Animals
Pharmacology (medical)
Ataxin-3
Caenorhabditis elegans
Caenorhabditis elegans Proteins
Pharmacology
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
Neurodegeneration
Neurodegenerative Diseases
medicine.disease
biology.organism_classification
Phenylbutyrates
3. Good health
Cell biology
030104 developmental biology
Spinocerebellar ataxia
TFEB
Original Article
Neurology (clinical)
Trinucleotide repeat expansion
Machado–Joseph disease
030217 neurology & neurosurgery
medicine.drug
Zdroj: Neurotherapeutics
ISSN: 1878-7479
1933-7213
DOI: 10.1007/s13311-020-00993-5
Popis: Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is a polyglutamine expansion disease arising from a trinucleotide CAG repeat expansion in exon 10 of the gene ATXN3. There are no effective pharmacological treatments for MJD, thus the identification of new pathogenic mechanisms, and the development of novel therapeutics is urgently needed. In this study, we performed a comprehensive, blind drug screen of 3942 compounds (many FDA approved) and identified small molecules that rescued the motor-deficient phenotype in transgenic ATXN3 Caenorhabditis elegans strain. Out of this screen, five lead compounds restoring motility, protecting against neurodegeneration, and increasing the lifespan in ATXN3-CAG89 mutant worms were identified. These compounds were alfacalcidol, chenodiol, cyclophosphamide, fenbufen, and sulfaphenazole. We then investigated how these molecules might exert their neuroprotective properties. We found that three of these compounds, chenodiol, fenbufen, and sulfaphenazole, act as modulators for TFEB/HLH-30, a key transcriptional regulator of the autophagy process, and require this gene for their neuroprotective activities. These genetic-chemical approaches, using genetic C. elegans models for MJD and the screening, are promising tools to understand the mechanisms and pathways causing neurodegeneration, leading to MJD. Positively acting compounds may be promising candidates for investigation in mammalian models of MJD and preclinical applications in the treatment of this disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13311-020-00993-5.
Databáze: OpenAIRE
Externí odkaz: